KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bionano Genomics (BNGO) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $11.9 million.

  • Bionano Genomics' Operating Expenses fell 6641.38% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.9 million, marking a year-over-year decrease of 5708.96%. This contributed to the annual value of $104.4 million for FY2024, which is 5357.74% down from last year.
  • Latest data reveals that Bionano Genomics reported Operating Expenses of $11.9 million as of Q3 2025, which was down 6641.38% from $11.3 million recorded in Q2 2025.
  • Bionano Genomics' 5-year Operating Expenses high stood at $116.0 million for Q3 2023, and its period low was $11.3 million during Q2 2025.
  • For the 5-year period, Bionano Genomics' Operating Expenses averaged around $30.7 million, with its median value being $29.0 million (2021).
  • Per our database at Business Quant, Bionano Genomics' Operating Expenses soared by 24148.36% in 2023 and then crashed by 6942.51% in 2024.
  • Bionano Genomics' Operating Expenses (Quarter) stood at $29.0 million in 2021, then skyrocketed by 35.52% to $39.3 million in 2022, then tumbled by 30.36% to $27.4 million in 2023, then tumbled by 43.93% to $15.4 million in 2024, then decreased by 22.46% to $11.9 million in 2025.
  • Its last three reported values are $11.9 million in Q3 2025, $11.3 million for Q2 2025, and $11.4 million during Q1 2025.